Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Paola Cappello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5321-7794; OpenAlex author ID A5050414562. Sources: OpenAlex.

Their work

Papers
39 (first author 5, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: 1 paper · 2016: 4 papers · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers

Papers 39

  1. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.08.021↗
  2. The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-25-4154↗
  3. Multi-omics and functional analysis of a bioengineered vascularized pancreatic cancer model reveal an immunosuppressive and therapy-resistant niche Co-author DOI 10.64898/2026.03.05.709702↗
  4. The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma. Last author DOI 10.1002/ctm2.70442↗
  5. Exploiting pancreatic cancer metabolism: challenges and opportunities. Co-author DOI 10.1016/j.molmed.2024.03.008↗
  6. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Co-author DOI 10.1186/s13046-024-03080-1↗
  7. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector r… Co-author DOI 10.3389/fimmu.2024.1427424↗
  8. Multiplexed Imaging Mass Cytometry Analysis in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.3390/ijms25031389↗
  9. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  10. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-325117↗
  11. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Co-author DOI 10.1053/j.gastro.2021.12.242↗
  12. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  13. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Last author DOI 10.1073/pnas.2020395118↗
  14. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Co-author DOI 10.1136/jitc-2021-002876↗
  15. Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance. Co-author DOI 10.1158/1535-7163.mct-20-0981↗
  16. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Co-author DOI 10.3390/molecules26061642↗
  17. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. Co-author DOI 10.1136/jitc-2020-001071↗
  18. Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Co-author DOI 10.1158/2326-6066.cir-19-0403↗
  19. Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. Co-author DOI 10.1186/s13046-020-01665-0↗
  20. The dark side of immunotherapy: pancreatic cancer. Last author DOI 10.20517/cdr.2020.13↗
  21. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317570↗
  22. The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevent… Co-author DOI 10.1002/path.5072↗
  23. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Last author DOI 10.1080/2162402x.2017.1393596↗
  24. Soluble stroma-related biomarkers of pancreatic cancer. Co-author DOI 10.15252/emmm.201708741↗
  25. Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. Co-author DOI 10.3390/cancers10020051↗
  26. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Co-author DOI 10.1186/s13045-016-0385-8↗
  27. Endogenous glutamine decrease is associated with pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.20545↗
  28. A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies. Co-author DOI 10.1016/j.aanat.2015.11.010↗
  29. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2015.1085147↗
  30. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. First author DOI 10.1158/2159-8290.cd-15-1346↗
  31. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. First author DOI 10.3892/ijo.2016.3524↗
  32. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3572↗
  33. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. First author DOI 10.1097/mpa.0000000000000160↗
  34. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell … Co-author DOI 10.1007/s00262-013-1429-3↗
  35. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.01.020↗
  36. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. First author DOI 10.1186/1756-8722-6-67↗
  37. A self antigen reopens the games in pancreatic cancer. Co-author DOI 10.4161/onci.24384↗
  38. Molecular and genetic bases of pancreatic cancer. Co-author DOI 10.2174/138945012800564077↗
  39. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. First author DOI 10.1021/pr100213b↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francesco Novelli · 32 shared papers, 2011–2026 · strength 2.89
  2. Claudia Curcio · 8 shared papers, 2017–2025 · strength 1.08
  3. Silvia Brugiapaglia · 6 shared papers, 2020–2025 · strength 0.98
  4. Cecilia Roux · 6 shared papers, 2017–2025 · strength 0.78
  5. Elisa Giovannetti · 4 shared papers, 2021–2026 · strength 0.67
  6. Miriam Martini · 4 shared papers, 2021–2024 · strength 0.65
  7. Federica Marchesi · 4 shared papers, 2016–2026 · strength 0.63
  8. Gianluca Mucciolo · 4 shared papers, 2020–2025 · strength 0.62
  9. Aldo Scarpa · 7 shared papers, 2011–2023 · strength 0.57
  10. Vincenzo Corbo · 4 shared papers, 2021–2023 · strength 0.46
  11. Giulia Adriani · 2 shared papers, 2025–2026 · strength 0.45
  12. Maria Chiara De Santis · 2 shared papers, 2023–2024 · strength 0.41
  13. Giorgia Tiberi · 2 shared papers, 2024–2025 · strength 0.40
  14. Alessandro Zerbi · 3 shared papers, 2016–2026 · strength 0.35
  15. Claudio Doglioni · 2 shared papers, 2023–2026 · strength 0.34
  16. Massimo Falconi · 2 shared papers, 2023–2026 · strength 0.34
  17. Enza Lonardo · 1 shared paper, 2026 · strength 0.30
  18. Silvia Carrara · 1 shared paper, 2026 · strength 0.30
  19. Claudio Luchini · 1 shared paper, 2026 · strength 0.30
  20. Manuel Gentiluomo · 1 shared paper, 2026 · strength 0.30
  21. Salvatore Paiella · 1 shared paper, 2026 · strength 0.30
  22. Paola Allavena · 4 shared papers, 2016–2020 · strength 0.29
  23. Marco Erreni · 2 shared papers, 2020–2024 · strength 0.28
  24. Bruno Bockorny · 1 shared paper, 2024 · strength 0.28
  25. Francesca Cordero · 2 shared papers, 2020–2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.